Diagnostic accuracy in detecting malignancy in suspicious skin lesions using Artificial

Intelligence

Authors: Miguel Sánchez-Viera[1], Alfonso Medela[2], Isabel del Campo[1], Jordi Barrachina[2],

Concetta D'Alessandro[1], Alejandra Vallejos[1], Alejandra Capote[1], Andy Aguilar[2], Taig Mac

Carthy[2], Gerardo Fernández[2], Antonio Martorell[2]

[1] IDEI, Instituto de Dermatología Integral. Avenida Menéndez Pelayo, 67 28009 Madrid, Spain.

[2] Legit.Health. Calle Gran Vía Diego López de Haro, 1, 48001 Bilbao, Spain.

Corresponding author:

Alfonso Medela

Department of Medical Computer Vision and PROMs, Legit.Health

Calle Gran Vía Diego López de Haro, 1, 48001 Bilbao, Spain

alfonso@legit.health

Funding: This study was co-funded by the European Union (NextGenerationEU) through the

Public Business Entity Red.es (State Secretariat for Digitalization and Artificial Intelligence,

Ministry of Economic Affairs and Digital Transformation) within the framework of the 2021

Call for Grants for research and development projects in artificial intelligence and other digital

technologies, and their integration into value chains (C005/21-ED), with file number

2021/C005/00154001

Conflict of Interests: Alfonso Medela, Andy Aguilar, Taig Mac Carthy, Gerardo Fernández and

Antonio Martorell are shareholders and Board Members of AI Labs Group S.L. Jordi Barrachina

is an employee of AI LABS GROUP S.L.

Ethical approval: Ethics committee of HM Hospitales (Comité Ético de Investigación con

medicamentos) gave ethical approval for this work, under reference number 24.12.2266-GHM.

Ethical statement: The patients in this manuscript have given written informed consent to

participate in this study.

Data availability statement: All data produced in the present study are available upon

reasonable request to the authors.

Manuscript word count: 3089

Abstract word count: 505

References: 20

Figures: 1

Supplementary figures: 0

Tables: 5

Supplementary tables: 2

Keywords: melanoma, oncology, deep learning, medical device, artificial intelligence

ABSTRACT

Background: Artificial Intelligence (AI) has demonstrated a high image processing capacity and
improved diagnostic accuracy in dermatology. In this context, Computer-Aided Diagnosis (CAD)
systems have shown a diagnostic performance comparable to that of specialists in classifying skin
lesions, particularly pigmented lesions. The present study aims to validate Legit.Health is a reliable
tool for diagnosing and assessing the severity of patients with skin lesions suspicious of
malignancy.

Objective: To validate that the Legit.Health medical device optimises clinical workflow by
enhancing diagnostic accuracy and determining the malignancy or severity of patients with skin
lesions suspicious of malignancy.

Methods: An observational, prospective study was conducted, incorporating both longitudinal
and retrospective cases. A total of 76 retrospective patients with 88 lesions and 32 prospective
patients with 42 lesions attending Instituto de Dermatologia Integral Madrid, Spain, were recruited.
The diagnostic performance of Legit.Health was compared with that of dermatologists in the
retrospective images against a gold standard (biopsy results). In the prospective phase of the study,
the performance of the current Legit.Health medical device was evaluated alongside
dermatologists assisted by the device and the latest version of the device (Legit.Health Plus).
Analyses were performed to calculate the AUC (area under the curve), accuracy, sensitivity, and
specificity.

Results: In the retrospective analysis, the device demonstrated an AUC of 0.76 compared to 0.79
for dermatologists in detecting malignant lesions. For these images, the device achieved the
following accuracy scores: top-1 = 0.23, top-3 = 0.38, and top-5 = 0.47, whereas dermatologists
achieved top-1 = 0.33 and top-3 = 0.45 (providing only three possible diagnoses). When the
specific histologic subtype of naevus was not considered in the diagnosis, Legit.Health achieved
an accuracy of top-1 = 0.50, top-3 = 0.71, and top-5 = 0.78, compared to dermatologists' top-1 =
0.50 and top-3 = 0.70. In the prospective analysis, we examined the performance of dermatologists
using the Legit.Health medical device, the device alone, and the latest version of the device. In the
malignancy analysis, they achieved an AUC of 0.94, 0.95, and 0.97, respectively. Regarding
diagnostic accuracy, dermatologists assisted by the medical device achieved a top-1 accuracy of
0.30, while both the medical device alone and its latest version achieved top-1 accuracies of 0.22
and 0.26, respectively, which increased to 0.44 and 0.52 when expanding to top-5. When the
specific histologic subtype of naevus was not considered in the diagnosis, accuracies increased to
0.85, 0.74, and 0.81, respectively, further improving as top-K was increased to top-5, reaching
0.89 and 0.93, respectively.

Conclusions: The device's diagnostic capability in distinguishing malignant conditions is on par
with that of expert dermatologists. This confirms its reliability as a tool for detecting skin

malignant categories in ICD-11, assisting in prioritising patients based on urgency and directing
them to the appropriate specialist or consultation.

INTRODUCTION

Image-based Artificial Intelligence (AI) has significant potential to enhance the accuracy of visual
diagnosis in the medical field[1],[2]. During the COVID-19 pandemic, limited access to in-person
healthcare services drove changes in medical care, accelerating the adoption of telemedicine[3]. In
this context, AI-assisted triage and decision support can be essential in helping healthcare
professionals manage workload and improve efficiency[4],[5].

In dermatology, pigmented lesions are among the most common conditions, generating high
demand in dermatology centres[6]. The triage, clinical assessment, and follow-up of these patients
require in-person resources and the dedicated time of specialists and their teams. The
implementation of AI-driven tools could support these professionals in streamlining such
processes and optimising workload management.

Advances in image recognition and interpretation, as well as AI, have driven innovations in
diagnosing various conditions, including dermatological diseases. Computer-aided diagnosis
(CAD) systems and other algorithm-based technologies have demonstrated their ability to classify
lesion images with a performance comparable to that of expert clinicians[7],[8].

Thus, progress in image recognition and AI has led to innovations in the diagnosis of skin
lesions[2],[9]. With appropriate development and rigorous evaluation, this technology could enhance
diagnostic accuracy. Studies have shown that AI algorithms can classify images of lesions,
including melanoma, with an expertise level comparable to that of dermatologists[10].

The advent of computer vision has revolutionised the identification of dermatological conditions,
representing a major opportunity to improve the diagnostic process[11],[12]. Among the key trends that
have contributed to improved patient survival rates are preventive measures and early diagnosis
campaigns[13]. Therefore, based on our previous research, we propose an AI-based system to assess
the malignancy of skin lesions and optimize diagnosis.

This study will evaluate the Legit.Health medical device, an AI-powered tool designed to optimise
clinical workflow and patient management for dermatological conditions. The purpose of this
system is to automatically prioritise patients with greater urgency, determine the appropriate type
of consultation (dermatological or aesthetic), enhance diagnostic capacity, assist auxiliary staff in
detecting malignant pigmented lesions, and provide a visual record (photographic evidence) of the
condition for subsequent expert review.

The primary objective of this study is to validate whether the Legit.Health medical device
improves efficiency in clinical workflow and patient management for individuals with

dermatological conditions. This will be achieved by assessing the tool's capability to diagnose and
determine the severity of skin lesions suspicious of malignancy. Ultimately, this will lead to a
reduction in the need for in-person consultations and lower patient care costs by ensuring that cases
are directed to the appropriate consultation type from the outset.

MATERIALS AND METHODS

Study Design

A prospective observational study with both longitudinal and retrospective case series was
conducted, beginning on 2 February 2024 and concluding on 23 August 2024. Patients with lesions
suspected of skin malignancy were recruited from the IDEI dermatology centre. Demographic data
and image-processing data were obtained using the Legit.Health medical device. The study
protocol was approved by the Research Ethics Committee for Medicines at HM Hospitals, under
reference: 24.12.2266-GHM.

Study population

All included patients were adults (≥18 years old) with lesions suspected of skin malignancy.
Prospective patients were recruited during their dermatology consultation at IDEI. No medications
or additional treatments were administered as part of this study. Retrospective images were
selected from patients with histologically studied lesions (both benign and malignant, pigmented
and non-pigmented). Retrospective data provided insights into historical diagnostic patterns,
whereas prospective data reflected more recent cases, allowing assessment of the device's utility
in real-time clinical scenarios.

Data collection and outcome measures

Patients were recruited during their dermatology consultation at IDEI. Those who met the
inclusion criteria were enrolled in the study. A photograph was taken of the lesion prompting the
consultation; if a patient had multiple lesions requiring dermatological examination, images were
captured for each lesion. For retrospective patients dermoscopic and clinical images were included,
using those with the best quality. .. For prospective patients, the following data were recorded: age,
sex, the clinical diagnosis made by the investigator, the recommended course of action (lesion
excision, follow-up, or referral for a cosmetic treatment when no suspicious of malignancy), the
histopathological diagnosis (if available), malignancy scoring assigned by the investigator (scale
of 1 to 10) and by Legit.Health (scale of 1 to 100), as well as the top-1, top-3, and top-5 diagnostic
predictions from Legit.Health. It is important to highlight that in the prospective study, only lesions
that appeared suspicious to the clinical or to Legit.Health were excused. Therefore, non-suspicious
lesions were not excised and we do not have histological confirmation. However, these lesions
were included in the concordance analysis between the clinical diagnosis and that of the device. .

For retrospective cases, in addition to these data, the top-1 and top-3 diagnoses provided by the
investigator (up to three possible diagnoses) and confirmation of malignancy were also recorded.
For prospective patients, all images used were clinical, while for retrospective patients
dermoscopic and clinical images were collected in the study.

Photo capture Procedure

All skin lesions were photographed following these technical guidelines:

- Uncompressed image formats such as PNG, HEIC, or TIFF
- Taken with a smartphone equipped with a minimum camera resolution of 13 megapixels
- All images had post-processing features disabled, including HDR, portrait mode, colour
filters, and digital zoom.
- Dermoscopic images were captured using Fotofinder medicam 1000, videodermatoscope
from FotoFinder Systems GmbH3Gen Inc.

Statistical analysis

For diagnostic performance evaluation, histopathological examination served as the reference
standard in both retrospective and prospective studies. Various statistical analyses were conducted
to assess and compare the performance of dermatologists and the medical device.

The area under the curve (AUC) was calculated to first evaluate the diagnostic performance of
dermatologists and the medical device in detecting malignancy, and second to compare the
performance of dermatologists assisted by the Legit.Health medical device, the Legit.Health
device alone, and the latest version of the device. Sensitivity and specificity were also computed.

For skin lesion recognition, top-K accuracy was calculated. This metric measured the frequency
with which the correct diagnosis was among the device's or dermatologists' top predictions. It was
assessed for dermatologists, the Legit.Health device, and the latest version of the medical device
(Legit.Health Plus). For this study, K values of 1, 3, and 5 were used. Differences in diagnostic
performance between retrospective and prospective studies were evaluated, attributing
improvements to the homogeneity of the prospective lesion dataset and the assistance provided by
the medical device.

RESULTS

Dataset

The dataset included 88 images from 76 different retrospective patients, of which 77 were dermatoscopic and 11 were clinical images, including for the analysis only the best quality images, clinical or dermoscopic.. Each lesion had a single corresponding image.

The dataset also included 120 images from 42 lesions in 32 different prospective patients. Each lesion had up to three images. All prospective images were clinical. Prospective lesions were also captured alongside the dermatologist's recommendation regarding their excision.

Retrospective analysis

The malignancy results demonstrate a similar diagnostic performance between dermatologists and the medical device. Specifically, dermatologists and the medical device achieved an AUC of 0.79 and 0.76, respectively. In terms of sensitivity and specificity, dermatologists reached a sensitivity of 86% and a specificity of 36%, while the medical device recorded a sensitivity of 81% and a specificity of 52%. These values were derived using a threshold of 10, as recommended by the manufacturer. The malignancy results indicate a greater tendency among dermatologists to diagnose malignant pathologies. The confirmed diagnostic data from this part of the study are presented in Supplementary Table 1.

Supplementary Table 1. Diagnosed diseases in retrospective study patients and their percentage within the 86 analysed samples.

Condition	Lesions (n, %)
Seborrheic keratosis	15 (17.44)
Basal cell carcinoma	14 (16.3)
Junctional melanocytic nevus	12 (14.0)
Compound nevus	9 (10.4)
Nevus	8 (9.3)

Intraepidermal carcinoma	5 (5.8)
Junctional nevus	5 (5.8)
Actinic keratosis	4 (4.6)
Léntigo	4 (4.6)
Benign keratosis	3 (3.5)
Blue nevus	2 (2.3)
Melanoma	2 (2.3)
Non-specific lesion	2 (2.3)
Dermatofibroma	1 (1.2)

190 For the pathological diagnosis analysis, two samples from the dataset were excluded due to the
191 absence of a clear pathological result. The analysis revealed comparable performance between
192 dermatologists and the medical device, as shown in Table 1. It is important to note that for this
193 evaluation, dermatologists provided up to three alternative diagnostic results.

194 **Table 1.** Diagnostic accuracy results from dermatologists and medical device

	Top-1 Accuracy	Top-3 Accuracy	Top-5 Accuracy
Dermatologist	0.33	0.45	-
Medical device	0.23	0.38	0.47

Upon reviewing the set of diagnoses, it was observed that 36 of the 86 images (42%) corresponded
to different histologic subtypes of naevi. Among these, dermatologists and medical device
misclassified the specific histologic type of naevus (ie.: Junctional nevus, compound nevus, …) in
24 and 27 out of the 36 cases, respectively.

To provide a broader view of diagnostic performance, the evaluation criteria were adjusted to
consider whether any diagnosis of a nevus as correct when a nevus was identified, regardless of
its specific type. With this generalised approach, the number of misclassifications was reduced to
2 for dermatologists and 0 for the medical device. This adjustment led to a significant improvement
in performance for both, with enhanced top-K accuracy and even a top-5 accuracy for the medical
device surpassing that of dermatologists. The results are presented in Table 2.

Table 2. Diagnostic accuracy results for dermatologists and the medical device after grouping different types of naevi under the general category of "nevus."

	Top-1 Accuracy	Top-3 Accuracy	Top-5 Accuracy
Dermatologist	0.56	0.70	-
Medical device	0.50	0.71	0.78

Prospective analysis

The prospective analysis involves evaluating the performance of three different sources: dermatologists assisted by the current medical device Legit.Health, the medical device Legit.Health on its own, and the latest version of the medical device. For the pathological diagnosis assessment, 15 out of the 42 samples without a confirmed pathological examination were excluded due to the fact that these lesions were not excised, though they were included in the diagnosis concordance analisis. The confirmed diagnostic data from this part of the study are presented in Supplementary Table 2.

Supplementary table 2. Diseases diagnosed in prospective patients of the study and percentage within the 27 samples analysed.

Condition	Lesions (n, %)
Melanocytic nevus	12 (44.4)
Seborrheic keratosis	3 (11.1)
Basal cell carcinoma	3 (11.1)
Junctional nevus	3 (11.1)
Capillary angioma	1 (3.7)
Dermal melanocytosis	1 (3.7)
Atypical nevus	1 (3.7)
Blue nevus	1 (3.7)
Lentiginous junctional nevus	1 (3.7)
Actinic keratosis	1 (3.7)

The malignancy results, as shown in Table 3, demonstrate strong diagnostic performance across
all three diagnostic sources, with an AUC exceeding 0.94. In particular, dermatologists achieve an
85% malignancy detection rate when assisted by the Legit.Health medical device. The medical
device performs a more conservative diagnosis, leading to the identification of a greater number
of malignant pathologies. Sensitivity and specificity statistics were calculated using a threshold of
10, as recommended by the manufacturer. However, as shown in Figure 1, this threshold can be
adjusted for the medical device to improve specificity without a loss of sensitivity.

Figure 1. Relation between sensitivity and specificity.

Table 3. Malignancy diagnostic performance results for prospective patients.

	AUC	Sensibility	Specificity
Dermatologist + Medical device Legit.Health	0.94	88%	85%
Medical device Legit.Health	0.95	100%	71%
The latest version of the device	0.97	100%	74%

It is important to highlight that the prospective evaluation results include the dermatologist's
recommendation to monitor or excise the lesion. As expected, this recommendation closely aligns
with the malignancy index measured by the medical device.

Regarding diagnostic accuracy, we found that the top-K accuracy of dermatologists, when
supported by the medical device, is comparable to that of the device operating independently, as
shown in Table 4.

Table 4. Diagnostic accuracy results for dermatologists and the medical device.

	Top-1 Accuracy	Top-3 Accuracy	Top-5 Accuracy
Dermatologist + Medical device Legit.Health	0.30	–	–
Medical device Legit.Health	0.22	0.33	0.44
The latest version of the medical device	0.26	0.37	0.52

As in the retrospective cases, we found that some samples correspond to various types of naevi.
Among these cases, 60–80% of naevi cases are misclassified when attempting to identify the
specific histologic subtype of nevus. However, when disregarding the exact histologic subtype, all
dermatologists are assisted by the Legit.Health medical device, the device on its own, and the latest
version of the medical device makes no diagnostic errors in the naevus samples, leading to
improved top-K accuracy. Notably, dermatologists assisted by the medical device nearly triple
their accuracy, while the medical device achieves a top-1 accuracy approaching that of
dermatologists. The results are presented below in Table 5.

Table 5. Diagnostic accuracy results for dermatologists and the medical device after grouping
different types of naevi under the general category of "nevus."

	Top-1 Accuracy	Top-3 Accuracy	Top-5 Accuracy
Dermatologist + Medical device Legit.Health	0.85	–	-
Medical device Legit.Health	0.74	0.85	0.89
The latest version of the medical device	0.81	0.93	0.93

The results from the prospective sample demonstrate that the latest version of the current medical
device outperforms the Legit.Health medical device across all metrics.

DISCUSSION

This study demonstrated that the medical device Legit.Health achieved strong performance in
detecting malignancy in patients with lesions suspicious of skin malignancy and supporting the
diagnosis of cutaneous pathologies using both dermoscopic and clinical images. The results were
comparable to those of an expert dermatologist.

The primary objective of the study was to improve the clinical workflow and care process for
patients with lesions suspicious of skin malignancy by enhancing diagnosis and severity
assessment. In the malignancy analysis of retrospective images, the device achieved an AUC
similar to that of dermatologists for malignancy detection. In terms of sensitivity and specificity,
sensitivity was nearly identical (86% for dermatologists vs. 81% for the device), while specificity
was nearly 20% higher. These malignancy results indicate a greater tendency among

dermatologists to diagnose malignant pathologies, which, due to their more conservative approach,

could lead to increased resource utilisation in clinical dermatology practice [14]. It is important to

note that similar malignancy detection performance between the medical device and healthcare

professionals has been observed in previous studies with other models [15], further highlighting its

potential to optimise clinical workflow [16].

For the prospective image analysis, it was observed that dermatologists benefit from the use of the

medical device, demonstrating strong performance in detecting malignant lesions (AUC above

0.94) with high sensitivity and specificity, consistent with the current state of the-art [17, 18].

Additionally, both dermatologists and the medical device exhibit superior performance when

evaluating prospective lesions compared to retrospective ones. This disparity can be attributed to

several factors. First, prospective lesions originate from a smaller, more homogeneous dataset

consisting mainly of well-characterised pathologies such as seborrhoeic keratosis, basal cell

carcinoma, and nevus. In contrast, retrospective lesions show greater variability, including

pathologies such as dermatofibroma, melanoma, lentigo, and various carcinomas, which present

greater diagnostic challenges. Moreover, the improved performance in the prospective evaluation

can be attributed to the fact that dermatologists benefit from the medical device's assistance, which

analyses up to three images, including both, clinical and dermoscopic images, per lesion. By

contrast, in the retrospective evaluation, only a single image per lesion (clinical or dermoscopic)

was available for analysis.

In this study, a malignancy threshold can be applied to the medical device's malignancy score to

determine when excision may be necessary, providing valuable support for dermatologists' clinical

decision-making. Our analysis revealed that with a malignancy threshold set at 0.40, the medical

device can predict the need for excision with 90% accuracy. This information could assist

healthcare professionals in deciding patient treatment strategies, such as monitoring, biopsy, or

lesion excision, rather than solely providing a specific diagnosis based on clinical assessment.

These recommendations are closely related to the malignancy prediction generated by the device

[19].

Regarding diagnostic support, when the diagnosis of nevus was unified, it was observed in the

retrospective image analysis that the device performed similarly to the dermatologist [10] and even

outperformed them when considering the Top-5 pathologies. However, in the prospective image

analysis, dermatologists achieved a diagnostic accuracy of 85% when supported by the medical
device, increasing to 93% with the latest version of the device. This result reinforces the device's
intended use as a clinical decision-support tool. It is also important to highlight that Top-1 accuracy
was not a primary metric in this study, as the device is specifically designed to always provide the
top five predicted classes, aligning with its intended function as a decision support tool. It is also
relevant that the differences between different subtypes of melanocytic nevus are mainly
histological, thus a clinical-histological correlation does not always exist which should be taken
into consideration [20].

Additionally, image quality in this study likely influenced the device's performance. Higher-
quality images could have enhanced device functionality and provided more valuable information.
Factors such as ensuring that the image is centered on the lesion area and that it is clear and free
of hair can improve image quality, thereby preventing any negative impact on the device's
performance. In this way, the medical device is able to filter and discard images of low quality
with artifacts that can disturb the quality of the image. Thus, the use of the medical device enables
physicians to avoid processing these images.

After analysing the study results across both retrospective and prospective images, it can be
concluded that the medical device is a highly valuable tool for improving clinical workflow and
patient care in cases of lesions suspicious of skin malignancy. This is achieved through enhanced
diagnosis and malignancy prediction, as demonstrated in the prospective image dataset, where
dermatologists achieved strong malignancy detection results. This strong performance was
achieved despite the inherent bias in the dataset, which only includes lesions deemed sufficiently
suspicious to warrant a biopsy. It's also remarkable the ability of the device to analyse both clinical
and dermoscopic images, in the same way as a well-trained physician does. This ability is, in our
opinion, a clear advantage of working with a well-trained algorithm for both kinds of images and
add significant value to the information available to physicians

In summary, the device represents a cutting-edge solution in dermatological diagnostic support
and telemedicine. Its integration of machine learning algorithms, patient-centred approach, and
favourable safety profile position it at the forefront of advancements in dermatological technology.

CONCLUSIONS

The diagnostic capability of the device in distinguishing skin malignancy is on par with that of expert dermatologists, not only in teledermatology but also in in-person consultations, confirming its reliability as a malignancy screening tool within ICD-11 categories. It assists in prioritising patients based on urgency, ensuring appropriate referrals to specialists or relevant clinics, and serves as a diagnostic support tool, thereby facilitating clinical decision-making.

ACKNOWLEDGEMENTS

We extend our gratitude for the co-funding of this project (DERMATIA: Multicenter Implementation and Validation of an Artificial Intelligence Platform for Clinical Decision Support and Patient Management in Dermatology) by the European Union (NextGenerationEU) through the Public Business Entity Red.es (State Secretariat for Digitalization and Artificial Intelligence, Ministry of Economic Affairs and Digital Transformation) within the framework of the 2021 Call for Grants for research and development projects in artificial intelligence and other digital technologies, and their integration into value chains (C005/21-ED), with file number 2021/C005/00154001.

We thank Clinitax (http://clinitax.eu) for its support and role in securing funding and project management.

REFERENCES

1. Pinto-Coelho L. How Artificial Intelligence Is Shaping Medical Imaging Technology: A Survey of Innovations and Applications. Bioengineering (Basel). 2023 Dec 18;10(12):1435. doi: 10.3390/bioengineering10121435.

2. Li Z, Koban KC, Schenck TL, Giunta RE, Li Q, Sun Y. Artificial Intelligence in Dermatology Image Analysis: Current Developments and Future Trends. J Clin Med. 2022 Nov 18;11(22):6826. doi: 10.3390/jcm11226826.

3. Holderness H, Baron A, Hodes T, Marino M, O'Malley J, Danna M, Cohen DJ, Huguet N. Community Health Centers Uptake of Telemedicine During the COVID-19 Pandemic: Trends, Barriers, and Successful Strategies. J Prim Care Community Health. 2024 Jan-Dec;15:21501319241274351. doi: 10.1177/21501319241274351.

4. Iowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, Aldairem A, Alrashed M, Bin Saleh K, Badreldin HA, Al Yami MS, Al Harbi S, Albekairy AM. Revolutionizing healthcare: the role of artificial intelligence in clinical practice. BMC Med Educ. 2023 Sep 22;23(1):689. doi: 10.1186/s12909-023-04698-z.

5. Kololgi SP, Lahari CS. Harnessing the Power of Artificial Intelligence in Dermatology: A Comprehensive Commentary. Indian J Dermatol. 2023 Nov-Dec;68(6):678-681. doi: 10.4103/ijd.ijd_581_23.

6. Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I. Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol. 2011 Oct;165(4):865-73. doi: 10.1111/j.1365-2133.2011.10436.x.

7. Esteva A, Kuprel B, Novoa RA, et al. Dermatologist-level classification of skin cancer with deep neural networks, Nature. 2017; 542(7639): 115-118.

8. Haenssle HA, Fink C, Schneiderbauer R, et al; Reader study level-I and level-II Groups. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists., Ann Oncol. 2018;29(8):1836-1842.

9. Jeong HK, Park C, Henao R, Kheterpal M. Deep Learning in Dermatology: A Systematic Review of Current Approaches, Outcomes, and Limitations. JID Innov. 2022 Aug 23;3(1):100150. doi: 10.1016/j.xjidi.2022.100150.

10. Phillips M, Marsden H, Jaffe W, Matin RN, Wali GN, Greenhalgh J, McGrath E, James R, Ladoyanni E, Bewley A, Argenziano G, Palamaras I. Assessment of Accuracy of an Artificial Intelligence Algorithm to Detect Melanoma in Images of Skin Lesions. JAMA Netw Open. 2019 Oct 2;2(10):e1913436. doi: 10.1001/jamanetworkopen.2019.13436. Erratum in: JAMA Netw Open. 2019 Nov 1;2(11):e1916430. doi: 10.1001/jamanetworkopen.2019.16430.

11. Chan S, Reddy V, Myers B, Thibodeaux Q, Brownstone N, Liao W. Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations. Dermatol Ther (Heidelb). 2020 Jun;10(3):365-386. doi: 10.1007/s13555-020-00372-0.

12. De A, Sarda A, Gupta S, Das S. Use of Artificial Intelligence in Dermatology. Indian J Dermatol. 2020 Sep-Oct;65(5):352-357. doi: 10.4103/ijd.IJD_418_20.

13. Garrison ZR, Hall CM, Fey RM, Clister T, Khan N, Nichols R, Kulkarni RP. Advances in
Early Detection of Melanoma and the Future of At-Home Testing. Life (Basel). 2023 Apr
9;13(4):974. doi: 10.3390/life13040974.

14. Chen JY, Fernandez K, Fadadu RP, Reddy R, Kim MO, Tan J, Wei ML. Skin Cancer
Diagnosis by Lesion, Physician, and Examination Type: A Systematic Review and Meta-
Analysis.   JAMA   Dermatol.   2025   Feb   1;161(2):135-146.   doi:
10.1001/jamadermatol.2024.4382.

15. Winkler JK, Blum A, Kommoss K, et al. Assessment of Diagnostic Performance of
Dermatologists Cooperating With a Convolutional Neural Network in a Prospective
Clinical Study: Human With Machine. JAMA Dermatol. 2023;159(6):621–627.
doi:10.1001/jamadermatol.2023.0905.

16. Chan HP, Samala RK, Hadjiiski LM, Zhou C. Deep Learning in Medical Image Analysis.
Adv Exp Med Biol. 2020;1213:3-21. doi: 10.1007/978-3-030-33128-3_1

17. Haenssle HA, Fink C, Schneiderbauer R, Toberer F, Buhl T, Blum A, Kalloo A, Hassen
ABH, Thomas L, Enk A, Uhlmann L; Reader study level-I and level-II Groups; Alt C,
Arenbergerova M, Bakos R, Baltzer A, Bertlich I, Blum A, Bokor-Billmann T, Bowling J,
Braghiroli N, Braun R, Buder-Bakhaya K, Buhl T, Cabo H, Cabrijan L, Cevic N, Classen
A, Deltgen D, Fink C, Georgieva I, Hakim-Meibodi LE, Hanner S, Hartmann F, Hartmann
J, Haus G, Hoxha E, Karls R, Koga H, Kreusch J, Lallas A, Majenka P, Marghoob A,
Massone C, Mekokishvili L, Mestel D, Meyer V, Neuberger A, Nielsen K, Oliviero M,
Pampena R, Paoli J, Pawlik E, Rao B, Rendon A, Russo T, Sadek A, Samhaber K,
Schneiderbauer R, Schweizer A, Toberer F, Trennheuser L, Vlahova L, Wald A, Winkler
J, Wölbing P, Zalaudek I. Man against machine: diagnostic performance of a deep learning
convolutional neural network for dermoscopic melanoma recognition in comparison to 58
dermatologists. Ann Oncol. 2018 Aug 1;29(8):1836-1842. doi: 10.1093/annonc/mdy166.

18. Han SS, Park I, Eun Chang S, Lim W, Kim MS, Park GH, Chae JB, Huh CH, Na JI.
Augmented Intelligence Dermatology: Deep Neural Networks Empower Medical
Professionals in Diagnosing Skin Cancer and Predicting Treatment Options for 134 Skin
Disorders. J Invest Dermatol. 2020 Sep;140(9):1753-1761. doi: 10.1016/j.jid.2020.01.019.

19. Peris K, et al. European consensus-based interdisciplinary guideline for diagnosis and
treatment of basal cell carcinoma—update 2023. Eur J Cancer. 2023;192:113254.

20. Cantisani C, Ambrosio L, Annessi E, Longo C, Farnetani F, Pezzini C, Condorelli A,
Annessi G, Bonetti LR, Guida S, Cota C, Tammaro A, Chello C, Pellacani G.
Dermoscopic, Histological, Confocal Microscopy Correlation of Atypical-Dysplastic
Melanocytic Nevi. Dermatol Pract Concept. 2024 Jan 1;14(1):e2024036. doi:
10.5826/dpc.1401a36.